GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Shiller PE Ratio

Medigen Biotechnology (ROCO:3176) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medigen Biotechnology Shiller PE Ratio Historical Data

The historical data trend for Medigen Biotechnology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Shiller PE Ratio Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medigen Biotechnology's Shiller PE Ratio

For the Biotechnology subindustry, Medigen Biotechnology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Shiller PE Ratio falls into.



Medigen Biotechnology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Medigen Biotechnology's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Medigen Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.544/131.7762*131.7762
=-0.544

Current CPI (Mar. 2024) = 131.7762.

Medigen Biotechnology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.900 100.560 -1.179
201409 -2.270 100.428 -2.979
201412 -1.140 99.070 -1.516
201503 -1.040 99.621 -1.376
201506 -0.820 100.684 -1.073
201509 -0.920 100.392 -1.208
201512 -1.130 99.792 -1.492
201603 -0.820 100.470 -1.076
201606 -1.280 101.688 -1.659
201609 -1.080 101.861 -1.397
201612 -0.920 101.863 -1.190
201703 -0.810 102.862 -1.038
201706 -0.710 103.349 -0.905
201709 -0.700 104.136 -0.886
201712 -1.150 104.011 -1.457
201803 -0.360 105.290 -0.451
201806 -0.660 106.317 -0.818
201809 -0.720 106.507 -0.891
201812 -1.452 105.998 -1.805
201903 -0.610 107.251 -0.749
201906 0.410 108.070 0.500
201909 -0.630 108.329 -0.766
201912 -1.014 108.420 -1.232
202003 -0.510 108.902 -0.617
202006 -0.650 108.767 -0.788
202009 -0.790 109.815 -0.948
202012 -0.480 109.897 -0.576
202103 -0.461 111.754 -0.544
202106 -0.930 114.631 -1.069
202109 0.460 115.734 0.524
202112 0.550 117.630 0.616
202203 -0.590 121.301 -0.641
202206 -0.880 125.017 -0.928
202209 -0.840 125.227 -0.884
202212 -2.550 125.222 -2.683
202303 -0.681 127.348 -0.705
202306 -0.700 128.729 -0.717
202309 -0.340 129.860 -0.345
202312 -2.310 129.419 -2.352
202403 -0.544 131.776 -0.544

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medigen Biotechnology  (ROCO:3176) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Medigen Biotechnology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines